Mayo Clinic research ends major controversy in cancer research

ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer. The research may be accessed here: http://www.cell.com/cancer-cell/fulltext/S1535-6108(09)00387-0

This recent publication enhances the company's international activities to promote its cancer detection system and related technology through its ChromoCure Cancer Research & Diagnosis Centers program. The research further confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research.

ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.

The company's systems detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company's technology also objectively measures, with high precision, the level of cancer present and its stage of progression.